U.S. Markets closed
  • S&P Futures

    4,159.50
    -5.25 (-0.13%)
     
  • Dow Futures

    33,981.00
    -35.00 (-0.10%)
     
  • Nasdaq Futures

    13,905.25
    -14.00 (-0.10%)
     
  • Russell 2000 Futures

    2,229.70
    -8.70 (-0.39%)
     
  • Crude Oil

    61.10
    -0.25 (-0.41%)
     
  • Gold

    1,793.70
    +0.60 (+0.03%)
     
  • Silver

    26.58
    +0.01 (+0.04%)
     
  • EUR/USD

    1.2042
    +0.0003 (+0.0241%)
     
  • 10-Yr Bond

    1.5640
    +0.0020 (+0.13%)
     
  • Vix

    17.50
    -1.18 (-6.32%)
     
  • GBP/USD

    1.3942
    +0.0010 (+0.0683%)
     
  • USD/JPY

    108.0000
    -0.0430 (-0.0398%)
     
  • BTC-USD

    53,448.55
    -2,748.53 (-4.89%)
     
  • CMC Crypto 200

    1,230.94
    -32.02 (-2.53%)
     
  • FTSE 100

    6,895.29
    +35.42 (+0.52%)
     
  • Nikkei 225

    29,095.25
    +586.70 (+2.06%)
     

Brazilian health regulator Anvisa authorizes trials for GSK-Medicago COVID vaccine

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SAO PAULO, April 8 (Reuters) - Brazilian health regulator Anvisa approved on Thursday the beginning of clinical trials in the country for a new COVID vaccine developed by Canada's Medicago R&D Inc and GlaxoSmithKline PLC, Anvisa said in a statement.

Anvisa said the companies were authorized to conduct phase 3 trials in the country. The companies are planning to test the new vaccines in around 30,000 people, in the U.S., Canada, Europe and Latin America. Brazil may have around 3,500 volunteers for the trials.

This will be the fifth COVID vaccine clinical trial in Brazil. (Reporting by Eduardo Simoes and Tatiana Bautzer Editing by Chizu Nomiyama)